SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed on April 3, 2006, by Hemispherx Biopharma, Inc. (Note: The request metadata listed "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.). The report addresses events occurring on March 31, 2006, related to the preparation of the annual report for the fiscal year ended December 31, 2005.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the identified accounting errors relate to non-cash financing charges and do not affect the Company's revenues, cash flows from past or future operations, or its liquidity.
Material Changes and Accounting Restatement
- Accounting Error: An incorrect accounting principle was applied to certain Debentures and Warrants issued between March 2003 and August 2005.
- Specific Issues: The error involved the initial recording of the embedded conversion feature of the Debentures, the fair value of related warrants, and certain Debenture and Warrant price resets.
- Impact Period: Financial statements for periods from March 31, 2003, to December 31, 2005, are affected.
- Non-Reliance Notice: The Audit Committee and management concluded that previously issued financial statements (Forms 10-Q and 10-K) for the affected periods should not be relied upon.
- Deficient Filing: The Form 10-K for the year ended December 31, 2005, was filed without audited financial statements, rendering it deficient under the Securities Exchange Act.
Outlook, Management Commentary, and Risks
Management, in consultation with the audit committee and independent auditors BDO Seidman, LLP, anticipates filing an amendment to the 2005 Form 10-K containing audited financial statements within 30 days. The Company also plans to file amended Forms 10-Q for the quarters ended March 31, June 30, and September 30 of 2004 and 2005 as soon as practicable. The primary risk identified is the deficiency of the current annual report due to the lack of audited statements.
Investor Verification Checklist
- Verify the upcoming amendment to the Form 10-K for the year ended December 31, 2005, to obtain audited financial statements.
- Monitor the filing of amended Forms 10-Q for the quarters in 2004 and 2005 to review restated figures for convertible debt and additional paid-in capital.
- Confirm that the restatements remain non-cash in nature and do not alter historical revenue or operating cash flow figures.
- Review the specific details of the Debenture and Warrant price resets once the amended reports are available.